A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Inclusion Criteria (For renal impaired subjects):

- Classification by renal function based on eGFR

- Clinical, ECG, and laboratory findings consistent with renal dysfunction

- BMI of 18.0 to 38.0 kg/m2 inclusive

- Women of child bearing potential (WOCBP) and sexually active fertile men with partners
who are WOCBP must use non-hormonal highly effective birth control

- Slightly different inclusion criteria are defined in the protocol for healthy subjects

Exclusion Criteria:

- History of uncontrolled or unstable cardiovascular, respiratory, hepatic,
gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease
within 6 months of screening

- Evidence of rapidly deteriorating renal function, defined as a screening eGFR that has
decreased from a previous eGFR by ≥ 50% within the last 3 months

- Current or recent (within 3 months of study drug administration) clinically
significant gastrointestinal disease or gastrointestinal surgery (including
cholecystectomy) that could impact the absorption of study drug

- Any major surgery within 4 weeks of study drug administration.

- Other protocol defined exclusion criteria could apply